Distinction of hydatidiform moles (HM) from nonmolar specimens and subclassification of HMs as complete hydatidiform mole (CHM), partial hydatidiform mole (PHM), or early CHM (eCHM) are important for clinical practice and investigational studies but diagnosis based solely on morphology suffers from poor interobserver reproducibility. Recent studies have demonstrated the use of p57 immunostaining and molecular genotyping for improving diagnosis of HMs. After performing a validation study of both techniques on 24 archival products of conception specimens (7 CHMs, 8 PHMs, 9 nonmolar), we prospectively analyzed 42 cases, largely obtained from a gynecologic pathology consultation practice, for which there was any consideration of a diagnosis of HM. After satisfactory experience with prospective cases, a modified approach was adopted, with p57 immunostaining used in conjunction with morphology to triage cases for molecular genotyping. Final diagnoses for the prospective cases based on combined morphology and ancillary testing were 24 CHMs (including 7 eCHMs), 7 PHMs, and 11 nonmolar specimens. P57 immunostaining, performed on all 66 cases, was negative in all CHMs, with the exception of 1 case of molecularly confirmed CHM with diffuse p57 expression, and positive in all PHMs and nonmolar specimens, with the exception of 3 cases of molecularly confirmed PHMs with an equivocal extent of p57 expression. Molecular genotyping of 51 cases (24 validation, 27 prospective) yielded data consistent with p57 results in the 47 cases with unequivocal p57 expression patterns and was used to establish the diagnoses for the 4 cases with aberrant or equivocal p57 results. All 17 genotyped CHMs demonstrated androgenetic diploidy, including the CHM with retained p57 expression; this case also demonstrated trisomy of chromosome 11 (retained maternal allele), accounting for the aberrant p57 expression. The remaining 14 CHMs were diagnosed by morphology and negative p57 results alone. All 15 PHMs demonstrated diandric triploidy.
Abstract: Distinction of hydatidiform moles (HM) from nonmolar specimens and subclassification of HMs as complete hydatidiform mole (CHM), partial hydatidiform mole (PHM), or early CHM (eCHM) are important for clinical practice and investigational studies but diagnosis based solely on morphology suffers from poor interobserver reproducibility. Recent studies have demonstrated the use of p57 immunostaining and molecular genotyping for improving diagnosis of HMs. After performing a validation study of both techniques on 24 archival products of conception specimens (7 CHMs, 8 PHMs, 9 nonmolar), we prospectively analyzed 42 cases, largely obtained from a gynecologic pathology consultation practice, for which there was any consideration of a diagnosis of HM. After satisfactory experience with prospective cases, a modified approach was adopted, with p57 immunostaining used in conjunction with morphology to triage cases for molecular genotyping. Final diagnoses for the prospective cases based on combined morphology and ancillary testing were 24 CHMs (including 7 eCHMs), 7 PHMs, and 11 nonmolar specimens. P57 immunostaining, performed on all 66 cases, was negative in all CHMs, with the exception of 1 case of molecularly confirmed CHM with diffuse p57 expression, and positive in all PHMs and nonmolar specimens, with the exception of 3 cases of molecularly confirmed PHMs with an equivocal extent of p57 expression. Molecular genotyping of 51 cases (24 validation, 27 prospective) yielded data consistent with p57 results in the 47 cases with unequivocal p57 expression patterns and was used to establish the diagnoses for the 4 cases with aberrant or equivocal p57 results. All 17 genotyped CHMs demonstrated androgenetic diploidy, including the CHM with retained p57 expression; this case also demonstrated trisomy of chromosome 11 (retained maternal allele), accounting for the aberrant p57 expression. The remaining 14 CHMs were diagnosed by morphology and negative p57 results alone. All 15 PHMs demonstrated diandric triploidy.
All genotyped nonmolar specimens demonstrated biparental diploidy. This study validates p57 immunostaining as a prospectively applicable triage assay for the diagnosis of CHMs based on morphology and a negative p57 result. Molecular genotyping is validated as a method to confirm a diagnosis of CHM by demonstrating androgenetic diploidy and to resolve p57-positive cases into diandric triploid PHMs, biparental diploid nonmolar specimens, and the rare CHM with aberrant p57 expression. D istinction of molar from nonmolar specimens and the subclassification of hydatidiform moles as complete hydatidiform mole (CHM), partial hydatidiform mole (PHM), or early CHM (eCHM) are important for both clinical practice and investigational studies. The risk of persistent gestational trophoblastic disease (GTD) and hence, clinical management, differs for CHM, PHM, and nonmolar specimens. 3, 4, 19, 37, 40 Accurate ascertainment of risk of persistent GTD requires rigorous classification of cases in clinicopathologic studies. The diagnosis of hydatidiform moles can often be accomplished on the basis of morphologic assessment alone when characteristic features are well developed. However, a number of studies have demonstrated that the diagnosis of hydatidiform moles continues to suffer from poor interobserver reproducibility. 8, 18, 23 The subtypes of hydatidiform moles are subject to misclassification as one another, particularly when encountered at earlier gestational ages. In addition, certain nonmolar specimens, including hydropic abortuses (HAs), early abortuses (EAs) with prominent trophoblastic proliferation, and products of conception (POC) specimens with abnormal villous morphology (AVM) of the type associated with other genetic abnormalities (eg, trisomy), can simulate hydatidiform moles. 7, 10 The value of ancillary techniques, including immunohistochemical analysis of p57 expression and molecular genotyping, for improving the diagnosis of hydatidiform moles has been demonstrated in a number of recent studies. 5, 6, 9, 26, 32 These techniques exploit the unique genetic features of CHMs, PHMs, and nonmolar POC specimens. CHMs (including eCHMs) can be distinguished from PHMs and nonmolar specimens by immunohistochemical assessment of the expression of the paternally imprinted p57 gene. CHMs, which are most often characterized by androgenetic diploidy (lack maternal DNA), are characterized by a lack of p57 expression in villous stromal cells and cytotrophoblast whereas expression is retained in PHMs and nonmolar specimens, both of which have maternal DNA. Molecular genetic analysis of the type provided by commercially available DNA genotyping kits offers even greater diagnostic discriminatory capability in that CHMs, PHMs, and nonmolar abortuses can be specifically distinguished from one another based on the identification of the parental source of polymorphic alleles and their ratios. In particular, this analysis can discern androgenetic diploidy, diandric triploidy, and biparental diploidy to rigorously diagnose and distinguish CHMs, PHMs, and nonmolar specimens, respectively. Such analysis is most important for the diagnosis of PHMs, which continue to pose diagnostic difficulty and cannot be distinguished from nonmolar specimens, especially those exhibiting AVM of the type associated with other (nonmolar type) genetic abnormalities, because of shared p57 expression patterns.
We performed a validation study using archival material from molar and nonmolar POC specimens to assess the performance of these assays in our laboratory. We then conducted a prospective analysis of all POC specimens for which there was any consideration of the possibility of a diagnosis of hydatidiform mole, focusing on problematic consultation practice cases, to assess the value of these ancillary techniques in routine practice and establish an efficient algorithmic approach to these specimens.
MATERIALS AND METHODS

Validation Study
Thirty cases of molar and nonmolar POC specimens were selected from the routine Gynecologic Pathology Service files of The Johns Hopkins Hospital, Baltimore, MD. All cases were reviewed by 2 pathologists (B.M.R., R.S.V.) at a multiheaded microscope to select only those cases for which there was complete agreement that the morphologic features were fully diagnostic of the assigned diagnostic category (CHM, PHM, nonmolar). These cases were subjected to p57 immunohistochemical analysis and molecular genotyping (see below for methods and details regarding interpretation). Details of this validation study are reported elsewhere (Murphy, submitted). In brief, 24 cases yielded satisfactory and informative results for both p57 immunostaining and molecular genotyping, allowing for the application of these techniques to the prospective analysis. Seven specimens diagnosed as CHM demonstrated a negative p57 result and androgenetic diploidy (all homozygous). Eight specimens diagnosed as PHM demonstrated a positive p57 result and diandric monogynic triploidy (all heterozygous). Nine specimens diagnosed as nonmolar demonstrated a positive p57 result and biparental diploidy.
Prospective Analysis
Forty-two consecutive POC specimens for which there was any consideration of the possibility of a diagnosis of a hydatidiform mole were prospectively collected as they were encountered on the Johns Hopkins Gynecologic Pathology Consultation Service (JHGPCS; 36 cases) and the routine in-house Gynecologic Pathology Service (6 cases) of The Johns Hopkins Hospital, Baltimore, MD from July 2007 through August 2008. The cases were subjected to immunohistochemical analysis and molecular genotyping (see below).
Clinicopathologic features, including patient age, clinical impression, and the initial morphologic impression and/or reason for seeking consultation were recorded. A diagnostic impression based on review of morphology was formulated based on both published criteria for the differential diagnosis of hydatidiform moles versus abnormal POC specimens known to simulate moles and the collective diagnostic experience of members of the JHGPCS. Diagnostic categories used included CHM, eCHM, PHM, AVM, EA, and HA. In brief, CHM is characterized by enlarged edematous villi with moderate to marked circumferential trophoblastic hyperplasia, often with cytologic atypia, prominent central cistern formation, and trophoblastic inclusions. ECHMs have characteristic features including a redundant bulbous villous growth pattern, hypercellular myxoid villous stroma, a labyrinthine network of villous stromal canaliculi, karyorrhectic debris within the stroma, and at least focal trophoblastic hyperplasia on villi and the undersurface of the chorionic plate. Morphologic features of PHMs include the presence of 2 populations of villi (large, irregular, hydropic villi and small, immature, fibrotic villi), cisterns in some enlarged villi, markedly irregular villi with scalloped borders and stromal trophoblastic inclusions, and mild trophoblastic hyperplasia. 16, 17, 20, 25, 38, 39, 42, 43 AVM is a less well-defined entity in which villi have some features suggestive of PHM (irregular shapes and sizes with limited trophoblastic proliferation, occasionally with syncytiotrophoblastic ''snouts'') but lack fully diagnostic morphologic features of PHM; in some cases these changes are associated with genetic abnormalities such as trisomy (but not triploidy as in PHM). 7 EA is used to designate an early gestation in which the trophoblastic proliferation is sufficiently prominent to raise concern for an eCHM or CHM but is actually nonmolar; in these specimens, the trophoblastic proliferation is polarized and radiates from the tips of the villi in an orderly manner. HA is used for POC specimens exhibiting only villous edema without trophoblastic hyperplasia. The combined morphological, immunohistochemical, and molecular genetic data were used to formulate a final diagnosis for each case. After sufficient satisfactory experience with the cases, a modified diagnostic approach was adopted. P57 immunohistochemical analysis was used in conjunction with morphology to triage the selection of cases for molecular genotyping. If the morphology and p57 results were entirely consistent with a diagnosis of CHM (p57 negative with appropriate internal positive control-see below), the case was interpreted as such and not subjected to molecular analysis. If the p57 result was positive or equivocal, regardless of morphologic features, the case was subjected to molecular analysis.
P57 Immunohistochemistry
All cases (24 validation, 42 prospective) were subjected to immunohistochemical analysis. Formalin-fixed paraffin-embedded tissue sections (5 mm) were stained using a Ventana BenchMark XT automated immunostaining system (Tucson, AZ) with mouse monoclonal antibodies against p57 protein (Neomarkers, Fremont, CA) from a ready-to-use preparation without dilution. The presence or absence of nuclear positivity was assessed in villous stromal cells, cytotrophoblast, intermediate trophoblast, and maternal decidua. On the basis of the staining patterns reported in the literature indicating that virtually all CHMs entirely lack p57 expression in villous stromal cells and cytotrophoblast whereas PHMs and nonmolar abortuses diffusely express p57 in these cell types, the quantity of these cells expressing p57 was estimated by routine light microscopic assessment of all the villi present in the stained sections, without resorting to actual cell counting. Staining was semiquantitatively assessed as follows: negative (no staining in these cell types), limited (staining in <10% of these cell types), focally positive (staining in >10% but <50% of these cells types), and diffusely positive (staining in >50% of these cell types). The p57 immunostain result was then interpreted as ''positive'' when the extent of staining was diffusely positive in these cell types. This pattern of expression is consistent with all forms of nonmolar POC specimens (EA, HA, AVM) as well as PHMs and cannot distinguish among these entities. The p57 immunostain was interpreted as ''negative'' and satisfactory when maternal decidua and/or intermediate trophoblastic cells exhibited nuclear expression of p57 (serving as internal positive control) but villous stromal cells and cytotrophoblast were either entirely negative or demonstrated only limited expression (<10%). This negative result was then interpreted as consistent with a diagnosis of CHM. Nuclear expression in villous stromal cells and cytotrophoblast in the focally positive range (>10% but <50%) was considered an equivocal result, encompassing the 30% value used in one study as a cutoff for positive and negative results but allowing for a wider range to enable the use of quick visual estimation rather than cell counting to determine a result. 6 It should be noted that the vast majority of cases exhibited either diffuse positivity for p57 or complete lack of expression of p57 in the cytotrophoblast and villous stromal cells, so that equivocally staining results were a minimal problem.
Molecular Genotyping
All 24 validation cases and 28 of the 42 prospective cases were subjected to molecular genotyping, with prospective cases triaged on the basis of combined assessment of morphology and p57 results as described above. The AmpFlSTR Profiler kit (Applied Biosystems, Foster City, CA) was used for this analysis. Formalin-fixed paraffin-embedded tissue sections (10-mm, unstained) were prepared using polymerase chain reaction (PCR) precautions. A serial hematoxylin and eosin (H&E)-stained 5-mm section was used to identify well-separated areas of maternal decidua and villous tissue. An area of each tissue type (B0.5 to 1.0 cm in size) was circled with a marking pen on the H&E slide. An unstained slide was superimposed on top of the marked H&E slide and Pinpoint solution (Zymo Research, Orange, CA) was applied to the areas of interest. The tissue was removed from the slide and digested according to the manufacturer's protocol. DNA was further purified using QIAamp DNA spin columns (Qiagen, Valencia, CA). PCR amplification of 9 short tandem repeat (STR) loci and the amelogenin locus was performed, with thermal cycling conditions and capillary electrophoresis carried out according to the manufacturer's instructions. In brief, the PCR conditions were 951C for 11 minutes followed by 28 cycles of 941C for 1 minute, 591C for 1 minute, and 721C for 1 minute, followed by a final extension at 601C for 45 minutes. After amplification, 1 ml of multiplex PCR product was mixed with 9 mL of deionized formamide/GeneScan 500 (ROX) size standard (Applied Biosystems). Samples were denatured at 951C for 2 minutes and placed on ice for at least 1 minute before analysis on the ABI3100 Genetic Analyzer (Applied Biosystems).
Capillary electrophoresis data were analyzed (described in detail in a separate report; Murphy, submitted). In brief, both the maternal and villous tissues were analyzed to identify alleles at each locus. The villous tissue was further analyzed as follows. Every allele from the villous tissue was identified as being maternal, definitively nonmaternal (assumed paternal), or equivocal (unknown whether maternal or paternal because of shared alleles) in origin. For each locus with 2 alleles identified, the allelic ratio was calculated by dividing the peak height of the longer allele by the peak height of the shorter allele. Allelic ratios between 0.61 and 1.17 were considered to be consistent with diploidy. Allelic ratios between 0.33 and 0.60 or 1.5 and 2.0 were considered to be consistent with triploidy. Loci with 3 alleles identified were also considered consistent with triploidy. The origin of triploidy was determined when possible based on a combined evaluation of allele ratios and source for those alleles with sufficient polymorphism. Each locus was scored as being consistent with diploidy or triploidy or not informative. The interpretation of all loci had to be concordant for final interpretation. At least 2 informative loci were required for final interpretation.
RESULTS
Results for the validation cases are briefly summarized in the Methods section and reported in detail elsewhere (Murphy, submitted). Data for the prospectively analyzed cases are summarized in Table 1 .
The final diagnoses for the 42 prospective cases, based on the combined analysis of all results, were 24
CHMs (of which 7 were eCHMs), 7 PHMs, and 11 nonmolar specimens (including 7 categorized as AVM). Of the 24 CHMs, 23 exhibited characteristic complete loss of p57 expression in villous stromal cells and cytotropho-blast and 1 exhibited diffuse p57 expression in these cells ( Fig. 1 ). Eleven CHMs were subjected to molecular genotyping. The 10 with informative results all demonstrated androgenetic diploidy, with 9 homozygous (due to Diagnosis and Subclassification of Hydatidiform Moles monospermy) and 1 heterozygous (due to dispermy) (Fig. 2) . This latter case, which was the sole CHM with aberrant (retained) p57 expression, also demonstrated trisomy of chromosome 11. The origin of the extra copy of chromosome 11 could not be determined on the basis of the single marker for this chromosome provided in the genotyping kit because of the shared maternal and paternal alleles at this locus. Analysis with additional markers for chromosome 11 demonstrated that the trisomy was due to 2 paternal copies and 1 maternal copy of this chromosome (data not shown), similar to the one previously reported case of a molecularly confirmed androgenetic diploid (dispermic) CHM with diffuse expression of p57 due to a retained chromosome 11 of maternal origin. 15 Further analysis of this case is being pursued and will be detailed in a subsequent report. One CHM failed to generate informative molecular genotyping results but could be diagnosed as eCHM based on morphology and a negative p57 result. The remaining 13 CHMs were triaged by p57 results (all negative) and not subjected to molecular analysis. It should be noted that 2 cases of CHM (cases 33 and 34) represented sequential specimens from 1 patient whose initial specimen was originally diagnosed as PHM. Based on a plateauing serum human chorionic gonadotropin level, another curettage specimen was obtained, demonstrating persistent hydatidiform mole. Consultation was then requested to address whether both specimens were in fact CHMs rather than PHMs. Of the 7 PHMs, 4 exhibited characteristic diffuse expression of p57 in all cellular components ( Fig. 3 ) and demonstrated diandric triploidy (all heterozygous) by molecular genotyping (Fig. 4 ). Three cases of PHM had equivocal p57 results, characterized by partial staining of villous stromal cells and cytotrophoblast estimated to comprise more than 20% but less than 50% of these cells. In 1 of these (case 1), the initial morphologic impression was CHM based on the amount of trophoblastic hyperplasia; however, the p57 expression was greater than expected for that diagnosis yet not as diffuse as most PHMs and nonmolar specimens (Fig. 5 ). In another one (case 10), the villi were predominantly mildly hydropic rather than scalloped, with mild to moderate trophoblastic hyperplasia and an equivocal extent of p57 expression, making diagnosis of PHM versus CHM difficult (Fig. 5 ). In the third case (case 42), the villi had a spectrum of appearances ranging from larger hydropic ones with mild to moderate trophoblastic hyperplasia and inclusions to smaller fibrotic ones with limited trophoblastic hyperplasia, making distinction between CHM and PHM difficult. Repetition of immunostaining in 2 of these cases and staining of multiple blocks in 1 case yielded similar equivocal results. In these morphologically and immunohistochemically equivocal cases, the finding of diandric triploidy by molecular genotyping established a diagnosis of PHM for each ( Fig. 6 ).
All 11 nonmolar specimens, including those examples of AVM simulating PHM and cases of EA suggesting eCHM, exhibited diffuse p57 expression in all cellular components ( Fig. 7) . Molecular genotyping of 10 of these demonstrated biparental diploidy (Fig. 8) . The remaining nonmolar case (case 36) represented a follow-up specimen of an earlier molar case (CHM, case 11) and was sent to address the possibility of persistent CHM. This follow-up specimen lacked features of a molar pregnancy and expressed p57 in cytotrophoblast and villous stromal cells. The patient had not adhered to recommended clinical management (was noncompliant with contraception). In view of this history, the morphology, and the p57 result, this subsequent specimen (which had limited villous tissue too intimately admixed with decidua for analysis) was interpreted as a new conception and was not subjected to molecular genotyping. Another nonmolar case of interest (case 26) was sent in consultation to address a perceived discrepancy between flow cytometric data and fluorescent in situ hybridization (FISH) results. The former analysis demonstrated a diploid result whereas FISH using only probes for sex chromosomes yielded 3 signals (XYY) and was thought to indicate triploidy, raising concern for a PHM. On the basis of the morphologic features of an EA and biparental diploidy by molecular genotyping, this case was proven to be a nonmolar EA most likely having a sex chromosome trisomy. Analysis of the clinical impression relative to the final diagnosis revealed that most cases suspected as molar pregnancies, were CHMs. Of the 14 cases that were clinically suspicious for a molar gestation before evacuation, 11 were confirmed as such. These included 9 immunohistochemically and genetically confirmed CHMs (negative P57 result and androgenetic diploidy), 1 CHM confirmed by the p57 result alone, and 1 genetically confirmed PHM (diandric triploidy). The remaining 3 cases were found to be nonmolar (biparental diploidy). Conversely, 18 of 25 cases lacking a clinical impression of a molar pregnancy were in fact hydatidiform moles. These included 12 CHMs and 6 PHMs. Of these 12 CHMs, 2 were immunohistochemically and genetically confirmed (negative p57 result and androgenetic diploidy), 9 were confirmed by the p57 results alone, and 1 was confirmed by molecular genotyping despite aberrant p57 FIGURE 3 . Partial hydatidiform mole (PHM). A to E, Typical PHM is characterized by variably sized hydropic and scalloped fibrotic villi (A, B) with foci of mild trophoblastic hyperplasia (C, D) and trophoblastic inclusions (E). F, P57 expression is diffuse within nuclei of villous stromal cells and cytotrophoblast; molecular genotyping confirmed diandric triploidy (see Fig. 4 ). expression (see above) All 6 PHMs were genetically confirmed (diandric triploidy).
Although the review of the morphologic features alone allowed for the formulation of a consultative diagnostic impression that was most often confirmed by immunohistochemical and molecular genetic analysis in many cases, there were 15 cases for which the morphologic features were considered equivocal to some degree by members of the JHGPCS (Table 1 ''Morphologic Impression'' column). These cases most often concerned a differential diagnosis of PHM versus AVM and occasionally PHM versus CHM, confirming that diagnosis and subclassification of hydatidiform moles remains problematic even for experienced gynecologic pathologists.
DISCUSSION
CHMs occur at a rate of approximately 1 per 1000 pregnancies whereas PHMs occur at a rate of nearly 3 per 1000 pregnancies. 19, 33 On the basis of well-defined cases in the modern literature, the risk of persistent GTD after CHM is 15% to 20%, whereas persistent GTD after a PHM is 0.2% to 4%. 12, 21, 37, 44 Although most cases of persistent GTD after a hydatidiform mole are invasive moles, 3% to 5% present as choriocarcinoma. Until recently, overtly malignant (metastatic) GTD was not thought to occur after a PHM; however, 3 cases of choriocarcinoma and 1 case of placental site trophoblastic tumor, all arising from antecedent well-documented PHMs, have been described in the literature (in the 3 cases of choriocarcinoma, identical microsatellite polymorphisms were documented in the antecedent PHM and the subsequent GTD). 34, 41 Hence, although localized and metastatic persistent GTD is much more common after a diagnosis of CHM, it can and does occur after a PHM. Thus, accurate classification of abnormal POC specimens is critical to ascertaining the actual risk of persistent GTD associated with the various subtypes of hydatidiform moles and determining the appropriate nature and duration of clinical follow-up care.
The literature is replete with studies showing poor reproducibility in the diagnosis of hydatidiform moles. 23, 24 Even among expert placental pathologists, high interobserver and intraobserver variability exists. 18 This is more commonly found with early gestations and most pronounced when the differential diagnosis concerns PHM. Our experiences in this study, one earlier study, 7 and our clinical practice confirm that this diagnostic difficulty persists even for experienced gynecologic pathologists. In view of the established limitations of morphologic assessment alone and the clinical importance of accurate diagnosis of molar specimens, use of ancillary techniques to refine the diagnosis of hydatidiform moles is recommended.
A variety of ancillary techniques have been used to improve upon the morphologic diagnosis of hydatidiform moles, including formal cytogenetic analysis (karyotyping), assessment of ploidy status by flow cytometry (on fresh, frozen, or paraffin-embedded material), image analysis or FISH, [27] [28] [29] numerous molecular (genotyping) techniques to assess maternal and paternal chromosomal contributions, including most recently the application of various STR multiplex PCR assays, 2, 11, 31 and immunohistochemistry for the paternally imprinted gene p57. 22, 35 In addition, some recent studies have used a combination of techniques (p57 immunohistochemistry and a molecular technique) to refine the diagnosis of hydatidiform moles. 5, 30 Some of these techniques suffer from a variety of limitations. Karyotyping is a time-intensive and laborintensive technique performed on fresh tissue that is largely not applicable to routine daily practice and cannot discern between maternal and paternal chromosomal contributions. The various ploidy techniques, including FISH, are sufficiently accurate, in most instances, to separate diploid, triploid, tetraploid (and aneuploid) specimens on fresh, frozen and paraffin-embedded tissue, but can, at times, be technically challenging and occasionally have results that are difficult to interpret because of debris and contamination (maternal tissue). However, more importantly, they also lack the ability to discern the exact maternal and paternal chromosomal contributions in a given specimen. Although these techniques have improved the overall interobserver reproducibility in the diagnosis of hydatidiform moles in general, this is limited mainly to increasing the reproducibility for the diagnosis of PHMs (those found to be triploid). 18 Of the various modern molecular adjunctive techniques used in numerous studies, most are performed in research settings. A recent study, however, applied a readily available multiplex STR PCR (AmpFISTR Identifiler PCR Amplification system) to 52 archival cases of hydatidiform moles and those entities that simulate moles and concluded that it was an accurate, cost-effective, time-sensitive ancillary molecular technique applicable to daily practice for classifying molar pregnancies. 5 The value of this method, in contrast to the other methods of ploidy determination mentioned above, is that the exact maternal and paternal chromosomal contributions can be determined to specifically distinguish diploid androgenetic CHMs from diploid nonmolar specimens and triploid diandric PHMs from triploid digynic nonmolar specimens.
After performing our own internal validation process on archival cases, we used this same straightforward kit-based molecular technique and immunohistochemical analysis of p57 expression in a prospective analysis focused on challenging consultation cases. We found that both techniques perform quite well. Although some minor contamination issues (maternal tissue admixed with villous tissue) did occur in the molecular genetic analysis, there were no cases in which contamination precluded a definitive interpretation of the genotyping results. Only 1 prospective case failed to amplify sufficiently for evaluation. One limitation encountered with this analysis concerns specimens in which only villous tissue is available for analysis. Lack of maternal decidual tissue precludes determination of the parental source of polymorphic alleles and their ratios. The exception to this limitation (encountered in 1 of our cases of CHM lacking maternal decidual tissue for analysis) is the finding of homozygosity at all tested loci in the villous tissue, a result that can be interpreted as most consistent with a CHM despite lack of maternal tissue for comparison because of the exceedingly low probability that a biparental specimen would exhibit homozygosity at all loci. The only other potential limitation of this molecular assay would be in the evaluation of the rare cases of biparental CHM. This is a single gene disorder presenting clinically, morphologically, and immunohistochemically (negative p57 result) as a CHM, with a presumed autosomal recessive pattern of inheritance mapped to 19q13.4 that has a risk of persistent GTD similar to that of conventional CHM (uniparental androgenetic diploidy). 1, 13, 14 Molecular genotypic analysis in such a case would result in biparental diploidy that could be misinterpreted as a nonmolar gestation in the absence of correlation with morphologic features and p57 results. Furthermore, infrequent yet well-documented cases of mosaicism and chimerism found in hydatidiform moles might lead to results that are difficult to interpret. 22 In addition to ploidy assessment and the various types of molecular genetic analysis, the use of immunohistochemical analysis of p57 expression as an ancillary technique in the diagnosis of hydatidiform moles has been well established. 6, 22, 26, 35 However, this assay is limited to the distinction of CHM from PHM and nonmolar specimens (HA, EA, AVM) and cannot distinguish PHMs from nonmolar gestations. The interpretation of p57 immunohistochemistry is typically straightforward in that the cellular components in which p57 is differentially expressed (villous stromal cells and cytotrophoblast) are almost always uniformly negative or diffusely positive, allowing interpretation of the former pattern as consistent with a diagnosis of CHM. In our cases, nearly all p57 results were readily interpretable as negative or positive, with the exception of 3 equivocal results encountered in cases proven to be PHMs by molecular genotyping. In these cases there was expression in both cytotrophoblast and villous stromal cells but the extent of staining was focal (more than 10% but less than 50% of these cells). We chose this range for our definition of an equivocal result because it encompasses the 30% value used in one study as a cutoff for positive and negative results but allows for a wider range to enable use of quick visual estimation, rather than cell counting, for determining a result in routine practice. As this amount of staining is uncommonly encountered but of an equivocal extent, cases exhibiting this pattern of expression warrant molecular analysis if establishing a definitive diagnosis is necessary for clinical management or investigative studies. These equivocal results were different from the aberrant results encountered in other studies. Discordant p57 immunohistochemical expression in cytotrophoblastic cells and villous stromal cells has been reported in rare cases of placental mosaicism 22 ; we recently encountered a case of placental mesenchymal dysplasia associated with isolated placental mosaicism in which the cytotrophoblast was uniformly positive but villous stromal cells were essentially negative. Relaxation of imprinting (incomplete imprinting) has been suggested as a possible mechanism for the rare cases of weak but diffuse nuclear staining in cytotrophoblast and villous stromal cells in otherwise genetically confirmed CHMs. 22 A single case of aberrant diffuse p57 expression due to a retained maternally derived chromosome 11 in an androgenetic diploid (dispermic) CHM has been reported. 15 Our single case of a molecularly confirmed androgenetic diploid (dispermic) CHM with diffuse p57 expression attributable to trisomy 11 (due to the retained maternal chromosome 11) is the second such example reported.
Our experience with the validation and prospective analyses in this study led to the development of a diagnostic algorithm for the evaluation of POC specimens having any features suggesting the possibility of a hydatidiform mole. Evaluation of H&E slides is followed by immunohistochemical analysis of p57 expression. If the morphologic features suggest a CHM and the p57 result is negative with satisfactory internal positive control, a diagnosis of CHM can be confidently established. Cases with features suggesting the possibility of a hydatidiform mole, but lacking fully developed diagnostic morphologic features, and having a positive or equivocal p57 result should be subjected to further analysis if feasible. Molecular genotypic analysis using the AmpFlSTR Profiler kit PCR Amplification system on paraffin-embedded . Two loci demonstrate diandric triploidy. Each locus has 2 copies of the paternal (P) allele and 1 copy of the maternal (M) allele. The D13S317 locus establishes that the triploidy is diandric, monogynic (paternal:maternal allele ratio = 2:1); the CSF1PO locus establishes that the diandric triploidy is due to dispermy.
material is a reliable technique that provides the specific genetic information necessary for the distinction of CHM, including eCHM, from both PHM and nonmolar specimens simulating molar gestations (HA, EA, AVM). This technique, used in conjunction with morphology, also allows for specific diagnosis of PHM as a diandric triploid gestation, thus preventing misclassification of eCHM, AVM, and even digynic triploid specimens as PHM. Digynic triploid specimens do not exhibit the morphologic features of PHMs, 36, 45 but can cause confusion with PHMs if simple ploidy analysis or FISH, rather than molecular genotyping, is used without morphologic evaluation.
In routine practice, laboratories lacking access to these techniques can seek consultation from reference laboratories offering these assays. In the setting of limited resources, cases demonstrating any features suggestive of a hydatidiform mole can be diagnosed descriptively, indicating a concern for a molar gestation, with a recommendation that serum human chorionic gonadotropin levels be followed to guide subsequent management. In investigational pursuits, all molar specimens should be FIGURE 7. Nonmolar specimens. A and B, An example of abnormal villous morphology (AVM) is characterized by irregularly shaped scalloped villi with focal mild trophoblastic hyperplasia, simulating a partial hydatidiform mole (PHM). C, P57 is diffusely expressed in villous stroma cells and cytotrophoblast, identical to the pattern seen in PHM, precluding distinction of AVM from PHM; molecular genotyping confirmed biparental diploidy in this example of AVM (see Fig. 8 ). D and E, An example of an early abortus with prominent trophoblastic proliferation suggests the possibility of an early complete hydatidiform mole (CHM). F, Diffuse expression of p57 in villous stroma cells and cytotrophoblast virtually always refutes a diagnosis of CHM (F); molecular genotyping confirmed biparental diploidy (data not shown).
Am J Surg Pathol Volume 33, Number 6, June 2009 Diagnosis and Subclassification of Hydatidiform Moles evaluated with ancillary techniques to assure rigorous classification of cases, particularly when designed to ascertain risk of persistent GTD associated with the various subtypes of hydatidiform moles. Since submission of this manuscript, we have analyzed 12 additional cases (11 consultation cases, 1 routine in-house case). These included 5 CHMs (including 2 early CHMs), 4 PHMs, and 3 non-molar AVM specimens. The 5 CHMs were diagnosed by morphology and negative p57 results. The 4 PHMs were confirmed by molecular genotyping demonstrating diandric triploidy. The 3 non-molar specimens were confirmed by molecular genotyping demonstrating biparental diploidy. 
